scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Investment analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for shares of scPharmaceuticals in a report issued on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings per share of ($0.37) for the quarter, down from their previous estimate of ($0.31). The consensus estimate for scPharmaceuticals' current full-year earnings is ($1.53) per share. Leerink Partnrs also issued estimates for scPharmaceuticals' Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($0.70) EPS.
scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The firm had revenue of $11.75 million for the quarter, compared to the consensus estimate of $11.63 million.
SCPH has been the topic of a number of other reports. Maxim Group dropped their price target on scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of scPharmaceuticals in a report on Thursday, March 20th.
View Our Latest Stock Analysis on SCPH
scPharmaceuticals Stock Performance
Shares of scPharmaceuticals stock traded down $0.20 during mid-day trading on Monday, hitting $3.31. 284,049 shares of the stock were exchanged, compared to its average volume of 367,144. The company has a 50-day simple moving average of $2.64 and a 200 day simple moving average of $3.15. The company has a market capitalization of $174.74 million, a P/E ratio of -1.74 and a beta of 0.17. scPharmaceuticals has a 12 month low of $1.94 and a 12 month high of $5.65. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.
Institutional Investors Weigh In On scPharmaceuticals
A number of hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC raised its holdings in shares of scPharmaceuticals by 1.2% in the 4th quarter. AIGH Capital Management LLC now owns 4,174,367 shares of the company's stock worth $14,777,000 after purchasing an additional 50,000 shares during the period. King Luther Capital Management Corp raised its stake in scPharmaceuticals by 9.2% in the 1st quarter. King Luther Capital Management Corp now owns 3,121,170 shares of the company's stock valued at $8,209,000 after acquiring an additional 263,260 shares during the period. Rice Hall James & Associates LLC raised its stake in scPharmaceuticals by 41.3% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,398,057 shares of the company's stock valued at $3,677,000 after acquiring an additional 408,422 shares during the period. Nantahala Capital Management LLC raised its stake in scPharmaceuticals by 33.3% in the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company's stock valued at $3,540,000 after acquiring an additional 250,000 shares during the period. Finally, Kingdon Capital Management L.L.C. raised its stake in scPharmaceuticals by 25.0% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,000,000 shares of the company's stock valued at $2,630,000 after acquiring an additional 200,000 shares during the period. Institutional investors own 89.52% of the company's stock.
About scPharmaceuticals
(
Get Free Report)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
Featured Articles
Before you consider scPharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and scPharmaceuticals wasn't on the list.
While scPharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
